mRNA-1189 for EBV Infection
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment called mRNA-1189, an experimental vaccine designed to address Epstein-Barr Virus (EBV) infections. Researchers primarily assess the treatment's safety and its effects on the body's response. The study includes different groups, with some receiving varying doses of mRNA-1189 and others receiving a placebo, a harmless inactive substance. It seeks healthy individuals aged 18 to 30 and adolescents aged 12 to under 18 who have not been exposed to EBV. Participants will receive three injections over several months, with their health and reactions closely monitored. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if you have a chronic illness that requires ongoing medication changes, you may not be eligible to participate.
Is there any evidence suggesting that mRNA-1189 is likely to be safe for humans?
Researchers are conducting studies to determine the safety and tolerability of mRNA-1189. Some studies focus on the body's response and safety for individuals aged 18 to 30, as well as for 12 to 17-year-olds who have never contracted the Epstein-Barr virus (EBV).
Currently, detailed information about side effects or negative reactions to mRNA-1189 is unavailable. The study remains in its early stages, primarily assessing safety and tolerability. Early studies often test various doses to identify the safest amount.
It's important to note that mRNA-based vaccines, like those for COVID-19, have generally been well-received, although each treatment differs. Participation in the trial will help researchers gather more information about the safety of mRNA-1189.12345Why do researchers think this study treatment might be promising for EBV infection?
Researchers are excited about mRNA-1189 because it represents a novel approach to tackling Epstein-Barr Virus (EBV) infections. Unlike traditional antiviral medications or symptomatic treatments, mRNA-1189 uses messenger RNA technology to potentially train the immune system to recognize and fight the virus more effectively. This innovative mechanism could offer a more targeted and efficient way to manage EBV infections. Moreover, the use of mRNA technology, similar to recent advancements in vaccine development, suggests a promising new direction for creating treatments that are both effective and quick to produce.
What evidence suggests that mRNA-1189 might be an effective treatment for EBV infection?
Research shows that mRNA-1189, a new vaccine tested in this trial, is designed to protect against the Epstein-Barr Virus (EBV). This vaccine functions similarly to the COVID-19 mRNA vaccines, which have proven very effective. Although specific data on mRNA-1189's effectiveness in preventing EBV is not yet available, it is expected to help the immune system fight the virus or lessen the severity of the infection. Early studies on similar mRNA vaccines have shown promising results. Overall, mRNA-1189 aims to reduce the impact of EBV, a virus that can cause infectious mononucleosis, often called "mono" or "the kissing disease." Participants in this trial will receive different dose levels of mRNA-1189 or a placebo to evaluate its effectiveness and safety.24567
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 3 intramuscular injections of mRNA-1189 or placebo on Days 1, 57, and 169
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- mRNA-1189
Find a Clinic Near You
Who Is Running the Clinical Trial?
ModernaTX, Inc.
Lead Sponsor
Dr. Stephen Hoge
ModernaTX, Inc.
Chief Medical Officer
MD from Harvard Medical School
Stéphane Bancel
ModernaTX, Inc.
Chief Executive Officer since 2011
MBA from Harvard Business School, MSc in Engineering from École Centrale Paris